<DOC>
	<DOCNO>NCT00441974</DOCNO>
	<brief_summary>This 48-week open-label study local manufacture adefovir dipivoxil Tablet evaluate efficacy safety adefovir 10mg daily Chinese subject compensate CHB . Primary endpoint proportion subject achieve HBV DNA undetectable ( &lt; =1000 copies/mL Roche COBAS AMPLICOR HBV MONITOR Test ) week 48 . Approximately 1250 patient recruit 30 study center China . The subject offer 48 week open label adefovir dipivoxil treatment , assessment every three month , 12-week post study treatment follow-up prior study completion .</brief_summary>
	<brief_title>Adefovir Dipivoxil For The Treatment Of Chinese Compensated Chronic Hepatitis B ( CHB ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>Male female subject age 1865 year inclusive Documented chronic hepatitis B infection determine presence serum HBsAg least 6 month Serum HBV DNA ≥105 copies/ml HBeAg positive subject ≥104 copies/ml HBeAg negative subject ( Realtime PCR , LLQ=1000cp/ml ) study screen ( within 2 week baseline ) , respectively . ALT value ≥2 time upper limit normal ( ULN ) time screen , determine use laboratory range document ALT abnormal within 6 month prior study screen . Compensated liver disease follow laboratory clinical parameter study screen : prothrombin time ≤ 2 second normal direct bilirubin Albumin≥35g/L Total bilirubin ≤2.5mg/dL ( ≤ 43 µmol/L ) normal direct bilirubin No history variceal bleed No history encephalopathy No history ascites Willing able undergo two liver biopsy ( prior dosing , 48 week therapy ; apply subject enrol site liver biopsy require ) . Agree participate investigational trial undertake HBV systemic antiviral regimen participation study A subject eligible inclusion study follow criterion apply : Any serious active medical psychiatric illness hepatitis B , opinion investigator , would interfere patient treatment , assessment compliance protocol . This would include , may limit , renal , cardiac , pulmonary , vascular , neurogenic , digestive , metabolic ( diabetes , thyroid disorder , adrenal disease ) , immunodeficiency disorder , active infection cancer . Documented evidence active liver disease due cause include coinfection hepatitis C ( HCV ) , Subjects antiHCV positive HCV RNA undetectable consider HCV seropositive eligible coinfection hepatitis delta ( HDV ) coinfection HIV autoimmune hepatitis ( antinuclear antibody titre &gt; 1:160 ) Alanine aminotransferase ( ALT ) &gt; 10 time ULN screen history acute exacerbation lead transient decompensation Serum alpha fetoprotein ( AFP ) &gt; 50 ng/mL . Hepatocellular carcinoma evidence one following : suspicious focus ultrasound radiological examination positive ultrasound finding , serum alphafetoprotein &gt; 100ng/ml Adequate renal function define serum creatinine &gt; 1.5 mg/dL ( &gt; 130 µmol/L ) Adequate hematological function define : Absolute neutrophil count &lt; 1 x 10³/mm³ ( 1 x 10^9/L ) Platelets &lt; 80 x 10³/mm³ ( 80 x 10^9/L ) ; platelet &lt; 100 x 10³/mm³ ( 100 x 10^9/L ) Hemoglobin &lt; 12g/dL ( 120 g/L ) ( male ) &lt; 10 g/dL ( 100 g/L ) ( female ) Active alcohol drug abuse history alcohol drug abuse consider investigator sufficient hinder compliance treatment , participation study interpretation result . Use immunosuppressive therapy , immunomodulatory therapy ( include interferon thymosin ) , systemic cytotoxic agent within previous 6 month study . Use chronic antiviral agent ( e.g . lamivudine , adefovir dipivoxil , entecavir , famciclovir , tenofovir , FTC , ganciclovir , DAPD , LfMA , HBIg , etc . ) , Chinese herbal medicine know activity HBV within previous 3 month study ; use agent effect ALT reduction ( e.g . schisandra agent ) study . Received nephrotoxic drug ( e.g. , aminoglycosides , amphotericin B , vancomycin , cidofovir , foscarnet , cisplatinum , pentamidine etc . ) competitor renal excretion ( e.g. , probenecid within 2 month prior study screen expectation patient receive course study . Received hepatotoxic drug ( e.g. , anabolic steroid , ketaconazole , itraconazole , isoniazid , rifampin , rifabutin ) within 2 month prior study screen expect receive course study . Previous ( plan ) participation investigational trial involve administration investigational compound within 2 month prior study screen .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>adefovir dipivoxil</keyword>
	<keyword>compensate</keyword>
	<keyword>chronic hepatitis B</keyword>
	<keyword>Chinese</keyword>
</DOC>